GLP‑1 Atlas

When the scale stops moving

Most stalls are not plateaus. Distinguishing the two comes down to where you are on the dose ladder and how long the flat stretch has lasted.

The short version

  • Two flat weeks is not a plateau. Normal fluctuation covers a range wider than most people expect.
  • A flat stretch right after a dose increase is often water and glycogen shifting, not fat loss stopping.
  • A genuine plateau is a stable trend across four weeks or more at a stable dose.
  • Reduced energy expenditure at lower body weight is expected physiology, not a failure of the treatment.

Almost everyone on this treatment goes through a stretch where the number stops falling and concludes something has gone wrong. Usually nothing has. The difficulty is that a single daily weight carries far more noise than signal, and the noise is large enough to hide a month of real progress.

How much daily weight moves on its own

Body weight can swing by a couple of kilograms within a single day, driven by hydration, sodium intake, glycogen stores, gut contents and — for many people — the menstrual cycle. None of that is fat.

A fat loss of half a kilogram in a week is a genuinely good result. It is also smaller than the daily noise. Which means a single measurement can never tell you what is happening; only the trend across several weeks can.

Weigh consistently, read slowly. Same day, same time, before eating, after using the bathroom. Consistency matters far more than accuracy — a scale that reads a kilogram heavy but reads it every time still shows you the trend perfectly well.

Three things that look like a plateau and are not

1. The week after a dose increase

Appetite drops, carbohydrate intake often drops with it, and stored glycogen takes water with it as it goes. In the other direction, a change in eating pattern can add water back. Both produce flat or rising weeks that have nothing to do with fat.

2. Early treatment, still climbing to steady state

In the first month or two, blood levels are still rising toward their plateau. The appetite effect is not yet at full strength. A slow start is the expected shape of the curve, not evidence of non-response.

3. Composition changing under a stable number

If you are eating enough protein and doing resistance work, you can be losing fat and gaining lean tissue at similar rates. The scale reports the sum and shows you nothing. This is the best possible reason for a flat month, and the only way to see it is to measure something other than weight — circumferences, or how clothes fit, or a body composition estimate.

What a real plateau looks like

A genuine plateau is four or more weeks of a stable trend, at a stable dose, with intake unchanged. When that happens, the usual explanations are:

  • Lower energy expenditure at lower weight. A smaller body costs less to run. The deficit that produced the first 10 kg does not exist any more at the new weight — this is arithmetic, not a metabolic malfunction.
  • Intake has drifted upward. Portions expand quietly as side effects fade and appetite partially returns.
  • The dose is below what you need. Some people plateau at an intermediate dose and resume when the next step arrives.
  • Absorption at the injection site. An overused area absorbs unpredictably. This is worth ruling out before anything else, because it is invisible and easy to fix.

What is worth doing about it

The order matters. Cheapest and most reversible first:

  1. Check the trend across four weeks rather than the last reading.
  2. Measure something besides weight — waist circumference is the single most informative addition.
  3. Check your injection sites for firm patches.
  4. Look honestly at whether intake has drifted.
  5. Then, and only then, discuss the dose with your prescriber.

A plateau is not a reason to increase your dose on your own. The ladder exists for a reason and skipping ahead reproduces the worst of the early side effects. If a dose change is warranted, it is a decision your prescriber makes with you.

The maintenance question

Some plateaus are not obstacles. If you have reached a weight that is healthier and sustainable, the flat line is the treatment succeeding at its second job. Weight maintenance is a legitimate endpoint, and one that most people arrive at without having decided in advance that they would.

How to read a trend properly

The single most useful change is to stop reading individual weights and start reading a line through them.

Weigh at the same time each day if that suits you, or weekly if daily readings are stressful — consistency matters more than frequency. Then look only at the average across a week, compared with the average across the week four weeks earlier. A weekly average removes most of the noise; a four-week comparison removes almost all of it.

Judged this way, most apparent plateaus disappear. What remains is a genuine flat line, and that is worth acting on rather than worrying about.

Measuring what the scale cannot see

  • Waist circumference. The single most informative addition to the scale, and the one people skip. Measured at the same point each time, it tracks visceral fat in a way weight does not.
  • How clothes fit. Unfashionable and remarkably sensitive to composition change.
  • Photographs. Same light, same position, monthly. Change that is invisible day to day is obvious across three months.
  • Strength in the gym. If you are getting stronger while the scale is flat, you are almost certainly gaining lean tissue and losing fat simultaneously.

Any one of these can reveal that a "plateau" was a composition change with a stable total — which is the best possible reason for a flat month and the one the scale is structurally incapable of showing you.

Sources

  1. Clinical trial data on weight trajectories with semaglutide and tirzepatide, including the shape and timing of the maintenance phase.
  2. Literature on adaptive changes in energy expenditure following weight reduction.

Related

Which medicine you are on

Everything above applies across the class, because it comes from a shared mechanism. The numbers that differ — dose ladders, missed-dose windows, in-use storage periods, half-lives — differ by product, sometimes substantially. Each medicine has its own reference here:

Ozempic · Wegovy · Mounjaro · Zepbound · Rybelsus · Saxenda · Victoza · Trulicity · all medicines

How this page is sourced. Figures come from manufacturers' approved labelling and from published clinical and pharmacokinetic literature. Regional labels differ, sometimes materially — where a number matters, the leaflet in your own box outranks anything written here. This site is not written or medically reviewed by clinicians, and we say so rather than implying otherwise; our editorial standards set out what that means and how corrections work.